5 research outputs found
Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P 2.26 µmol/L exhibited higher risk of cardiovascular death (sub-hazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients
Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P 2.26 µmol/L exhibited higher risk of cardiovascular death (sub-hazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients
Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P
Background and aims: Peripheral arterial disease (PAD) is a leading cause of morbimortality worldwide. Lipocalin-2 (LCN2) has been associated with higher risk of amputation or mortality in PAD and might be involved in muscle regeneration. Our aim is to unravel the role of LCN2 in skeletal muscle repair and PAD.
Methods and results: WT and Lcn2-/- mice underwent hindlimb ischemia. Blood and crural muscles were analyzed at the inflammatory and regenerative phases. At day 2, Lcn2-/- male mice, but not females, showed increased blood and soleus muscle neutrophils, and elevated circulating pro-inflammatory monocytes (p < 0.05), while locally, total infiltrating macrophages were reduced (p < 0.05). Moreover, Lcn2-/- soleus displayed an elevation of Cxcl1 (p < 0.001), and Cxcr2 (p < 0.01 in males), and a decrease in Ccl5 (p < 0.05). At day 15, Lcn2 deficiency delayed muscle recovery, with higher density of regenerating myocytes (p < 0.04) and arterioles (αSMA+, p < 0.025). Reverse target prediction analysis identified miR-138-5p as a potential regulator of LCN2, showing an inverse correlation with Lcn2 mRNA in skeletal muscles (rho = -0.58, p < 0.01). In vitro, miR-138-5p mimic reduced Lcn2 expression and luciferase activity in murine macrophages (p < 0.05). Finally, in human serum miR-138-5p was inversely correlated with LCN2 (p ≤ 0.001 adjusted, n = 318), and associated with PAD (Odds ratio 0.634, p = 0.02, adjusted, PAD n = 264, control n = 54).
Conclusions: This study suggests a possible dual role of LCN2 in acute and chronic conditions, with a probable role in restraining inflammation early after skeletal muscle ischemia, while being associated with vascular damage in PAD, and identifies miR-138-5p as one potential post-transcriptional regulator of LCN2
Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death
and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have
emerged as potential candidates for new biomarker discovery related to their protein and nucleic
acid cargo. In search of new prognostic and therapeutic targets in PAD, we determined the
prothrombotic activity, the cellular origin and the transcriptomic profile of circulating EVs. This
prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs
cellular origin and phosphatidylserine exposure were determined by flow cytometry in plateletfree plasma (n = 45 PAD). Transcriptomic profiles of medium/large EVs were generated using the
MARS-Seq RNA-Seq protocol (n = 12/group). The serum concentration of the differentially
expressed gene S100A9, in serum calprotectin (S100A8/A9), was validated by ELISA in control
(n = 100) and PAD patients (n = 317). S100A9 was also determined in EVs and tissues of human
atherosclerotic plaques (n = 3). Circulating EVs of PAD patients were mainly of platelet origin,
predominantly Annexin V positive and were associated with the procoagulant activity of plateletfree plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among
them, serum calprotectin was elevated in PAD patients (p < 0.05) and associated with increased
amputation risk before and after covariate adjustment (mean follow-up 3.6 years, p < 0.01). The
combination of calprotectin with hs-CRP in the multivariate analysis further improved risk
stratification (p < 0.01). Furthermore, S100A9 was also expressed in femoral plaque derived EVs
and tissues. In summary, we found that PAD patients release EVs, mainly of platelet origin, highly
positive for AnnexinV and rich in transcripts related to platelet biology and immune responses.
Amputation risk prediction improved with calprotectin and was significantly higher when combined with hs-CRP. Our results suggest that EVs can be a promising component of liquid biopsy
to identify the molecular signature of PAD patients
Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)
Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death
and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have
emerged as potential candidates for new biomarker discovery related to their protein and nucleic
acid cargo. In search of new prognostic and therapeutic targets in PAD, we determined the
prothrombotic activity, the cellular origin and the transcriptomic profile of circulating EVs. This
prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs
cellular origin and phosphatidylserine exposure were determined by flow cytometry in plateletfree plasma (n = 45 PAD). Transcriptomic profiles of medium/large EVs were generated using the
MARS-Seq RNA-Seq protocol (n = 12/group). The serum concentration of the differentially
expressed gene S100A9, in serum calprotectin (S100A8/A9), was validated by ELISA in control
(n = 100) and PAD patients (n = 317). S100A9 was also determined in EVs and tissues of human
atherosclerotic plaques (n = 3). Circulating EVs of PAD patients were mainly of platelet origin,
predominantly Annexin V positive and were associated with the procoagulant activity of plateletfree plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among
them, serum calprotectin was elevated in PAD patients (p < 0.05) and associated with increased
amputation risk before and after covariate adjustment (mean follow-up 3.6 years, p < 0.01). The
combination of calprotectin with hs-CRP in the multivariate analysis further improved risk
stratification (p < 0.01). Furthermore, S100A9 was also expressed in femoral plaque derived EVs
and tissues. In summary, we found that PAD patients release EVs, mainly of platelet origin, highly
positive for AnnexinV and rich in transcripts related to platelet biology and immune responses.
Amputation risk prediction improved with calprotectin and was significantly higher when combined with hs-CRP. Our results suggest that EVs can be a promising component of liquid biopsy
to identify the molecular signature of PAD patients